Analytical Chemistry · 2016 · 14 citations · 17 references
MedicinePharmacokineticsPharmacologyDrug DiscoveryDrug MetabolismMass Spectrometric AnalysisCytochrome P450-mediated MetabolismDrug DispositionDrug-drug Interactions In MetabolismDrug-metabolizing EnzymesEnzyme InhibitionMass SpectrometryCatalytic Activity AssaysCyp450-mediated InteractionsCytochrome P450 KineticsMatrix-assisted Laser Desorption/ionizationMetabolic Adverse Drug ReactionsMetabolic Enzyme InhibitionMetabolic Pathway InhibitionSelf-assembled Monolayers
The competition of two drugs for the same metabolizing enzyme is a common mechanism for drug-drug interactions that can lead to altered kinetics in drug metabolism and altered elimination rates in vivo. With the prevalence of multidrug therapy, there is great potential for serious drug-drug interactions and adverse drug reactions. In an effort to prevent adverse drug reactions, the FDA mandates the evaluation of the potential for metabolic inhibition by every new chemical entity. Conventional methods for assaying drug metabolism (e.g., those based on HPLC) have been established for measuring drug-drug interactions; however, they are low-throughput. Here we describe an approach to measure the catalytic activity of CYP2C9 using the high-throughput technique self-assembled monolayers for matrix-assisted laser desorption-ionization (SAMDI) mass spectrometry. We measured the kinetics of CYP450 metabolism of the substrate, screened a set of drugs for inhibition of CYP2C9 and determined the Ki values for inhibitors. The throughput of this platform may enable drug metabolism and drug-drug interactions to be interrogated at a scale that cannot be achieved with current methods.
17